Semaglutide vs. Liraglutide
This is a within-family comparison: both are GLP-1 receptor agonists from the same manufacturer lineage, separated by a molecular generation. Liraglutide lasts about a day; semaglutide's engineering stretches to a week.
Head-to-head and cross-trial data give semaglutide the edge on average weight loss and convenience. Liraglutide answers with the longest safety history in the class — and, with generics arriving, a cost profile the newer drugs can't match.
The facts, side by side
| Semaglutide | Liraglutide | |
|---|---|---|
| Regulatory status | FDA-approved drug | FDA-approved drug |
| Evidence level | Human clinical trials | Human clinical trials |
| Category | Weight Loss | Weight Loss |
Full profiles: Semaglutide · Liraglutide
Average results
Trial programs and head-to-head comparison show greater average weight loss with semaglutide (roughly mid-teens percent vs high single digits for liraglutide at weight-management doses). Both beat placebo convincingly; the gap between them is consistent.
Dosing rhythm
Daily injection versus weekly. Adherence research generally favors less frequent dosing, and the practical difference over months is real for many patients.
Track record and cost
Liraglutide has been in clinical use since 2010, with cardiovascular-outcome data and deep post-market history — and generic entry is making it the value option in an expensive class. Semaglutide's record is newer but already extensive.
The bottom line
Semaglutide wins the averages and the convenience; liraglutide holds the longevity record and, increasingly, the price argument. In a class where insurance coverage often decides, 'the GLP-1 your plan covers, prescribed by someone managing you properly' beats either name in the abstract.
Semaglutide vs. Liraglutide FAQ
More comparisons
Semaglutide vs. Tirzepatide
GLP-1 vs dual GIP/GLP-1 — how the two most prescribed weight-management peptides compare on evidence, average results, side effects and practical reality.
Tirzepatide vs. Retatrutide
One is an FDA-approved medicine; the other is an investigational triple agonist still in trials. The comparison that matters is regulatory status, not receptor count.
BPC-157 vs. TB-500
The internet's two favorite healing peptides compared honestly: different molecules, similar marketing, and the same missing ingredient — controlled human trials.
Build your own comparison